Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (151-160 of 281) with videos related to

Pageof 29
Sort By:
ESMO Open|March 10, 2020
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patientsGiovanni Crisafulli, Benedetta Mussolin, Andrea Cassingena, et al.
Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2023
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment FeaturesEnrico Berrino, Maria Costanza Aquilano, Emanuele Valtorta, et al.
Pathologica|December 22, 2010
Recommendations for mutational analysis of EGFR in lung carcinomaA Marchetti, N Normanno, , et al.
Cancers|March 19, 2020
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal CancerAnnalisa Lorenzato, Alessandro Magrì, Vittoria Matafora, et al.
Plos One|October 7, 2009
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerAndrea Sartore-Bianchi, Federica Di Nicolantonio, Michele Nichelatti, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2008
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesFederica Di Nicolantonio, Sabrina Arena, Margherita Gallicchio, et al.
Journal of Clinical Pathology|February 13, 2024
Clinicopathological characterisation of <i>MTAP</i> alterations in gastrointestinal cancersGianluca Mauri, Giorgio Patelli, Laura Roazzi, et al.
Breast Cancer Research : BCR|March 29, 2008
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancerCornelia Liedtke, Luca Cardone, Attila Tordai, et al.
Nature Medicine|May 3, 2016
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell deathChiara Pozzi, Alessandro Cuomo, Ilaria Spadoni, et al.
Pageof 29

Showing results (151-160 of 281) with videos related to

Sort By:
Pageof 29
ESMO Open|March 10, 2020
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patientsGiovanni Crisafulli, Benedetta Mussolin, Andrea Cassingena, et al.
Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2023
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment FeaturesEnrico Berrino, Maria Costanza Aquilano, Emanuele Valtorta, et al.
Pathologica|December 22, 2010
Recommendations for mutational analysis of EGFR in lung carcinomaA Marchetti, N Normanno, , et al.
Cancers|March 19, 2020
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal CancerAnnalisa Lorenzato, Alessandro Magrì, Vittoria Matafora, et al.
Plos One|October 7, 2009
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerAndrea Sartore-Bianchi, Federica Di Nicolantonio, Michele Nichelatti, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2008
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesFederica Di Nicolantonio, Sabrina Arena, Margherita Gallicchio, et al.
Journal of Clinical Pathology|February 13, 2024
Clinicopathological characterisation of <i>MTAP</i> alterations in gastrointestinal cancersGianluca Mauri, Giorgio Patelli, Laura Roazzi, et al.
Breast Cancer Research : BCR|March 29, 2008
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancerCornelia Liedtke, Luca Cardone, Attila Tordai, et al.
Nature Medicine|May 3, 2016
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell deathChiara Pozzi, Alessandro Cuomo, Ilaria Spadoni, et al.
Pageof 29